저분자 무균 주사제 시장 : 약물 유형, 제품 유형, 투여 경로, 용도, 유통 채널별 - 세계 예측(2024-2032년)

Global Small Molecule Sterile Injectable Drugs Market will observe a CAGR of 7.1% from 2024 to 2032, driven by the massive expansion of manufacturing facilities and capabilities of large pharmaceutical companies. These companies are investing heavily to expand their capabilities to meet the growing global demand for sterile injectables.

For instance, in February 2024, Selkirk Pharma, Inc., a United States-based private equity firm, acquired 1,000 shares and reported a successful Aseptic Process Simulation (APS) at its sterile manufacturing facility. The company specializes in pharmaceutical delivery injection, filling, and finishing of small molecules of drugs, including vaccines and synthetic chemicals, biopharmaceutical sponsors, and pharmaceutical products.

These compounds are important for many medical conditions, including infectious diseases, cancer, and chronic diseases. Extended manufacturing processes enable companies to improve the efficiency of their supply chains, improve product quality, and better meet regulatory standards. Furthermore, advances in technology and manufacturing enable the development of new drugs and therapies to drive market growth. The injectables market is poised for further expansion, meeting the growing healthcare needs across the globe with safe and effective injectable solutions.

Overall small molecule sterile injectable drugs industry size is classified based on drug type, product type, route of administration, application, distribution channel, and region.

The small molecule sterile injectable drugs revenue from the antibiotics segment will register a commendable CAGR from 2024 to 2032. Injectable antibiotics ensure rapid delivery and high bioavailability, making them useful in severe infections where oral therapy may be ineffective.

While antibiotic infectious disease resistance is increasing globally, healthcare providers rely increasingly on over-the-counter antibiotic injections to combat bacterial resistance and prevent complications. Companies continue to innovate in drug disinfection and manufacturing technology to meet requirements and regulatory standards. While the healthcare system continues to prioritize infection prevention and patient safety, the demand for over-the-counter injectable antibiotics remains important for infectious disease management.

The generic segment will witness an appreciable growth from 2024 to 2032. Generic sterile injectables offer cost-effective therapeutic options compared to brand counterparts, making them important in healthcare systems worldwide. These drugs are critical in various conditions such as infection, pain relief, and chronic diseases, ensuring access to affordable treatments for patients and healthcare providers. The generic sterile injectable market is expanding, driven by strict regulatory approvals for its standards of quality, ensuring that generic sterile injectables maintain performance and safety standards comparable to their registered counterparts.

Europe Small molecule sterile injectable drugs market will exhibit a notable CAGR from 2024 to 2032. An aging population, increasing rates of chronic diseases, and improvements in health care in the region support market growth. These drugs are important for the treatment of a wide range of conditions, including infection, cancer, and immune system diseases, providing effective and rapid relief through injections.

European market regulates strict compliance and emphasizes on quality standards, ensuring a safe and reliable supply of medicines. As pharmaceutical companies expand their manufacturing capacity and introduce new products, the demand for drug-free injectables continues to rise in Europe. This growth underlies the demand for healthcare services for patients to improve outcomes and optimize treatment options, making non-invasive injectables the cornerstone of modern injection healthcare practices at the county level.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Rising demand for personalised and targeted therapies
    • 3.2.1.3 Growing R&D investment accelerated activities
    • 3.2.1.4 Advancement in drug delivery technology
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of development and manufacturing
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antibiotics
• 5.3 Chemotherapy agents
• 5.4 Skeletal muscle relaxants
• 5.5 Anaesthetics
• 5.6 Anticoagulants
• 5.7 Anticonvulsants
• 5.8 Antivirals
• 5.9 Other drug types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Intravenous (IV)
• 7.3 Intramuscular (IM)
• 7.4 Subcutaneous (SC)

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Infectious diseases
• 8.4 Diabetes
• 8.5 Musculoskeletal
• 8.6 Autoimmune disorders
• 8.7 Cardiovascular diseases
• 8.8 CNS disorders
• 8.9 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amgen Inc.
• 11.3 AstraZeneca Plc.
• 11.4 BioCryst Pharmaceuticals, Inc.
• 11.5 Bristol-Myers Squibb Company
• 11.6 Eisai Co., Ltd.
• 11.7 Eli Lilly and Company
• 11.8 Fresenius Kabi USA
• 11.9 Gilead Sciences, Inc.
• 11.10 Merck KGaA
• 11.11 Novartis AG
• 11.12 Pfizer Inc.
• 11.13 Sanofi
• 11.14 Sun Pharmaceutical Industries Ltd.
• 11.15 Teva Pharmaceutical Industries Ltd.